Category:
BIOTECHNOLOGY
Medical Device News Magazine reports breaking biotechnology news in addition to medical device news.
Owlstone Medical Presents Data Demonstrating Progress in Development of Breath Biopsy Test for the Early Detection of Lung Cancer
The company announced new data on the development of a screening test for the early detection of lung cancer. The results and research progress were presented in two posters at the EACR 2023 Congress, the annual meeting of the European Association for Cancer Research, held June 12-15 in Torino, Italy.
SMi Discloses £6 Million Seed Funding Round
SMi notes the tnvestment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Nanotein Technologies Launches Revolutionary NK Cell Soluble Activator for Cancer Immunotherapy Research
Nanotein Technologies adds to its best-in-class NanoSpark™ reagent line, with the launch of NanoSpark™ GROW-NK, a high-performance reagent for the ex vivo activation and expansion of Natural Killer cells, in an easy-to-use, feeder cell free format.
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government Contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
“We are pleased to accept this award and collaboration with the U.S. Government to ensure that, as a society, we are better prepared for the next pandemic. This award validates our unique approach of combining antibody development and electrochemical-based diagnostics for a rapid response to save lives and manage infectious disease outbreaks,” stated Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.
Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections
Greg Merril, co-Founder and CEO of Adaptive Phage Therapeutics: "This investment will allow us to advance our lead clinical programs related to musculoskeletal infections, including prosthetic joint infections and diabetic foot osteomyelitis."
New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
“With the option for subcutaneous self-administration, crovalimab could help meet the lifelong needs of people living with PNH and their caregivers,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Genetech Global Product Development. “Data from the COMMODORE studies will be submitted to regulatory authorities around the world.”
DxVx, Won the Governmental Project to Develop Diagnostic Sensor Kit for Adult Diseases
In this project, which will be carried out over three years with a total budget of about $3.6 million($2.8 million in government support), Dx&Vx will lead the development as a lead company.
Hememics Biotechnologies, Inc. and General Graphene Corporation Cement Strategic Partnership for Large-Scale Production of Graphene-Based Biosensors
In the past nine months alone, Hememics in conjunction with General Graphene has manufactured more than 100,000 graphene biosensors. Using its patented desiccation technology for detection biology, Hememics has functionalized and tested these biosensors through numerous molecular and antigen tests to detect SEB and ricin at consistent sensitivities in the low picomolar range and get results within 5 minutes.
Telix Opens European Radiopharmaceutical Production Facility
Located in the heart of Belgium’s ‘Radiopharma Valley’, the 2,800 square metre facility is one of Europe’s largest radiopharmaceutical production facilities. It will serve as the primary manufacturing site for radioisotopes and commercial and clinical products for patients in the Europe Middle East and Africa (EMEA) region and beyond advises Telix.
